ClinicalTrials.gg
RecruitingNCT06233942Updated Sep 16, 2026

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

A Phase 1 interventional study of BG-C9074 and Tislelizumab in Advanced Solid Tumor, sponsored by BeOne Medicines. Recruiting at 37 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
308
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • BG-C9074
  • Tislelizumab
  • Advanced Solid Tumors
  • first-in-human
  • B7H4
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide a signed and dated written prior to any study-specific procedures, sampling, or data collection.
  2. (ECOG) Performance Status ≤ 1.
  3. Participants with selected or cytologically confirmed advanced, , and unresectable solid tumors who have previously received standard systemic therapy and whose cancer is not amenable to therapy with curative intent, and for whom further treatment is not available or not tolerated. Enrollment will be limited to participants with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/-) breast cancer, cholangiocarcinoma (CCA), endometrial cancer, squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or ovarian cancer. Enrollment in the Japan cohort will be limited to participants with HR+/HER2- breast cancer, TNBC, endometrial cancer, or ovarian cancer.
  4. ≥ 1 per , version 1.1 (RECIST v1.1)
  5. Able to provide an archived tumor tissue sample.
  6. Adequate bone marrow and organ function.
  7. Females of must be willing to use a highly effective method of for the duration of the study, and for ≥ 7 months after the last dose of study drug(s).
  8. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 4 months after the last dose of study drug(s).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with a B7 homolog 4 (B7H4)-targeting antibody-drug conjugate (ADC) or an ADC with a topoisomerase 1 inhibitor (TOP1i) payload.
  2. Active or uncontrolled, untreated
  3. Any ≤ 2 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
  4. History of interstitial lung disease, ≥ Grade 2 noninfectious pneumonitis, oxygen saturation at rest \< 92%, or requirement for supplemental oxygen (including intermittent use) at baseline.
  5. Uncontrolled diabetes.
  6. Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study treatment(s).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Part A (Monotherapy Dose Escalation)

    BG-C9074 monotherapy dose escalation

    Drug: BG-C9074

  • Experimental
    Phase 1a: Part B (Monotherapy Safety Expansion)

    BG-C9074 dose levels that have been determined to be safe and tolerable in Part A will be investigated.

    Drug: BG-C9074

  • Experimental
    Phase 1a: Part C (Combination Therapy Dose Escalation)

    BG-C9074 plus tislelizumab combination at the recommended dose for expansion (RDFE).

    Drug: BG-C9074 · Drug: Tislelizumab

  • Experimental
    Phase 1a: Part D (Japan Cohort)

    A separate cohort in Japan will evaluate the safety of BG-C9074 monotherapy in Japanese participants with select solid tumors

    Drug: BG-C9074

  • Experimental
    Phase 1b: Monotherapy Dose Expansion

    The monotherapy dose expansion phase will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a.

    Drug: BG-C9074

  • Experimental
    Phase 1b: Combination Therapy Dose Expansion (BG-C9074 plus tislelizumab)

    This arm will assess BG-C9074 plus tislelizumab as first-line therapy in select solid tumors after completion of the dose escalation phase.

    Drug: BG-C9074 · Drug: Tislelizumab

  • Experimental
    Phase 1b: Combination Therapy Dose Expansion (BG-C9074 plus bevacizumab)

    This arm will assess BG-C9074 plus bevacizumab in select solid tumors participants after establishing the recommended monotherapy dose and schedule.

    Drug: BG-C9074 · Drug: Bevacizumab

Interventions

  • DrugBG-C9074

    administered by intravenous infusion

  • administered by intravenous infusion

  • administered by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs (as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] Version \[v\] 5.0),, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.

    Time frame: Approximately 3 years

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C9074

    Defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 28% or the highest dose administered, respectively

    Time frame: Approximately 18 months

  3. Phase 1a: Recommended Dose for Expansion (RDFE) of BG-C9074.

    The potential RDFE(s) of BG-C9074 alone and in combination with tislelizumab will be determined based on the MTD or MAD, taking into consideration the long-term tolerability, PK, pharmacodynamics, preliminary antitumor activity, and any other relevant data, as available

    Time frame: Approximately 18 months

  4. Phase 1b: Overall Response Rate (ORR) as monotherapy and in combination with tislelizumab

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

    Time frame: Approximately 3 years

  5. Phase 1b: Recommended Phase 2 dose (RP2D) of BG-C9074 as monotherapy and in combination with bevacizumab or tislelizumab

    The RP2D of BG-C9074 will be determined based on safety, PK, pharmacodynamics, preliminary antitumor activity, and other relevant data, as available.

    Time frame: Approximately 30 months

Secondary outcomes

  1. Phase 1a: ORR as monotherapy and in combination with tislelizumab

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

    Time frame: Approximately 3 years

  2. Phase 1b: ORR as monotherapy and in combination with bevacizumab or tislelizumab

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

    Time frame: Approximately 3 years

  3. Phase 1b: ORR per B7-H4 (B7 homolog 4) protein expression

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1 and evaluated according to the amount of B7-H4 (B7 homolog 4) protein expressed in their tumors

    Time frame: Approximately 3 years

  4. Duration of Response (DOR)

    Duration of response (DOR) is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first, as assessed by the investigator

    Time frame: Approximately 3 years

  5. Duration of Response (DOR) per B7-H4 protein expression

    Duration of response (DOR) is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first, as assessed by the investigator, and evaluated according to the amount of B7-H4 protein expressed in the tumors

    Time frame: Approximately 3 years

  6. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease, as assessed by the investigator

    Time frame: Approximately 3 years

  7. Disease Control Rate (DCR) per B7-H4 protein expression

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease, as assessed by the investigator, and evaluated according to the amount of B7-H4 protein expressed in the tumors

    Time frame: Approximately 3 years

  8. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks as assessed by investigator.

    Time frame: Approximately 3 years

  9. Clinical Benefit Rate (CBR) per B7-H4 protein expression

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks as assessed by investigato, and evaluated according to the amount of B7-H4 protein expressed in the tumors

    Time frame: Approximately 3 years

  10. Phase 1b: Progression Free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

    Time frame: Approximately 3 years

  11. Phase 1b: Number of Participants with AEs and SAEs

    Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.

    Time frame: Approximately 3 years

  12. Maximum observed plasma concentration (Cmax) for BG-C9074

    Time frame: Twice in the first four months

  13. Minimum observed plasma concentration (Cmin) for BG-C9074

    Time frame: Approximately 3 years

  14. Time to reach maximum observed plasma concentration (Tmax) for BG-C9074

    Time frame: Twice in the first four months

  15. Half-life (t1/2) for BG-C9074

    Time frame: Twice in the first four months

  16. Area under the concentration-time curve (AUC) for BG-C9074

    Time frame: Twice in the first four months

  17. Apparent clearance (CL/F) for BG-C9074

    Time frame: Twice in the first four months

  18. Apparent volume of distribution (Vz/F) for BG-C9074

    Time frame: Twice in the first four months

  19. Accumulation ratio for BG-C9074

    Time frame: Twice in the first four months

  20. Plasma concentrations for BG-C9074

    Time frame: Approximately 3 years

  21. Phase 1a: Number of participants with anti-drug antibodies (ADAs) to BG-C9074 and tislelizumab

    Time frame: Approximately 3 years

  22. Phase 1b: Number of participants with anti-drug antibodies (ADAs) to BG-C9074

    Time frame: Approximately 3 years

  23. Serum concentration of BG-C0974

    Time frame: Approximately 3 years

  24. Serum concentration of Tislelizumab

    Time frame: Approximately 3 years

07

Study locations

33 of 37 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Jan 31, 2024
StartActual
Apr 12, 2024
Primary completionEst.
Sep 28, 2027
CompletionEst.
May 15, 2028
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06233942
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Apr 12, 2024
Primary completion
Sep 28, 2027 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
1.877.828.5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion